Notes: January 4, 2021, Eledon Pharmaceuticals, Inc., formerly known as Novus Therapeutics, Inc., a Delaware corporation (the “Company”), filed a Certificate of Amendment (the “Certificate of Amendment”) to its Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a change of the Company’s name from “Novus Therapeutics, Inc.” to “Eledon Pharmaceuticals, Inc.” effective as of January 5, 2021 (the “Name Change”). In connection with the Name Change, the Company’s ticker symbol changed to “ELDN” from “NVUS”. Trading under the new ticker symbol began on January 5, 2021. The Company’s new CUSIP number is 28617K101. <p> Oct. 2, 2020-- Novus Therapeutics, Inc. (NASDAQ : NVUS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-18. The effective time of the reverse stock split will be 12:01 a.m. (Eastern Time) on October 5, 2020. Novus common stock will begin trading on a split-adjusted basis commencing upon market open on October 5, 2020. As a result of the reverse split, every 18 shares of Novus’s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value $0.001 per share. Novus’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “NVUS,” but will be assigned a new CUSIP number, 67011N 204. <p> May 10, 2017 -- The business combination of Otic Pharma, Ltd. and Tokai Pharmaceuticals, Inc. (TKAI) will become effective on May 11, 2017. As a result the Common Stock of Tokai Pharmaceuticals, Inc. (TKAI) will undergo a one-for-nine (1-9) reverse stock split along with a change of name, symbol, and CUSIP number. New Company Name: Novus Therapeutics, Inc. New Symbol: NVUS New CUSIP: 67011N105